Searched for
SELL WOCKHARDT PHARMA LTD
Ahead of Market: 10 things that will decide stock market action on FridayIndian equities witnessed sharp swings before ending lower amid expiry-day volatility and rising geopolitical concerns. Profit booking in b...- Delhi HC allows Intas to sell cancer drug Bevatas, sets aside order favouring Sun PharmaThe Delhi High Court division bench has ruled in favor of Intas Pharmaceuticals, allowing the company to introduce its anti-cancer medicati...
- Ahead of Market: 10 things that will decide stock market action on TuesdayBenchmark indices Sensex and Nifty fell for a fourth straight session amid elevated crude oil prices, geopolitical tensions and persistent ...
- Ahead of Market: 10 things that will decide stock market action on MondayIndian equity markets ended sharply lower on May 29 amid broad-based selling, MSCI-driven flows and rising volatility. Technical indicators...
- Ahead of Market: 10 things that will decide stock market action on ThursdayDomestic equities surged as crude oil slipped below $100 and US-India trade optimism boosted sentiment. Nifty and Sensex gained over 1%, le...
- Buyout giants in talks with Wockhardt for domestic formulations businessThe individual suitors have indicated that they are interested in buying at least 51% stake in a deal that could value the biz at Rs 4,000-...
- Sell Wockhardt Pharma with a target of Rs 875: Mitesh ThackerSell Wockhardt Pharma with a target of Rs 875 and a stop loss of Rs 948
- Sell Wockhardt Pharma with a target of Rs 880: Mitesh ThackerSell Wockhardt Pharma with a target of Rs 880 and a stop loss of Rs 966
- Sell Wockhardt Pharma Ltd with target of Rs 188: Sandeep WagleIn a chat with ET Now, Sandeep Wagle, Founder & CEO of Power My Wealth, shares his view on Wockhardt Pharma Ltd.
- Some pharma stocks run out of steam; high valuations, regulatory issues lead to selloff pressure on StreetPharma stocks have become laggards of late, given their high valuations, regulatory issues and overall slowdown in sales.
- Wockhardt Pharma Q1 net at Rs 194 croreMumbai-based Wockhardt Pharma bounced back into the black with a net profit of Rs 193.96 crore in the first quarter ended June.
- Wockhardt told to clarify asset-sale plan to lendersThe Bombay High Court asked Wockhardt to clarify with its foreign lenders which assets the troubled pharma firm could sell during the pende...
- Wockhardt won't sell assets without noticeDebt-ridden pharma firm Wockhardt has assured foreign creditors such as Calyon, Barclays, and a trust, representing the foreign currency co...
- Wockhardt seeks HC nod to sell nutrition divisionTroubled drugmaker Wockhardt, which is undergoing a corporate debt restructuring (CDR) process, on Saturday asked the Bombay High Court’s p...
- Wockhardt puts marketing division Merind on blockAfter selling a slew of business divisions, Mumbai-based pharma company Wockhardt is learnt to have put its marketing division of pharmaceu...
- Wockhardt taps MNCs to sell Protinex, FarexIn a move to prune its debts, troubled pharma firm Wockhardt is in talks with a few MNCs to sell two of its best-selling brands - Protinex ...
- Wockhardt won't sell head-office in Mumbai: DirectorPharma major, Wockhardt on Friday said that it was looking at raising funds and was evaluating various options but selling its head-office,...
- Wockhardt may sell 2 foreign armsDrug major Wockhardt is looking for potential buyers for its French subsidiary Negma Laboratories to repay its debt to investors.
- Cos convert FCCBs at steep discountsThe recent phase of bullishness notwithstanding India Inc is in for a spot of bother what with many corporates having to convert their fore...
- Indian pharma cos look to Europe for growthCountry's leading pharma companies are looking towards Europe for organic and inorganic growth with the US market, the largest one for Indi...
Load More
